化疗相关心功能障碍:心脏磁共振定量参数及其预后意义
本研究纳入145例癌症合并心力衰竭患者,比较有无化疗相关心功能障碍(CTRCD)者的心脏磁共振定量参数,并分析其与主要不良心血管事件(MACE)的关联。CTRCD组原生T1、ECV和T2显著更高,指数化左心室质量更小;多变量Cox回归显示T2和定量LGE与MACE独立相关。
要点
- CTRCD患者原生T1、ECV、T2升高,指数化左心室质量减小。
- T2和定量LGE可能是CTRCD患者MACE的独立预后因素。
- 上述参数在轻中度与重度CTRCD之间无显著差异。
核心结论
- 心脏磁共振定量参数有潜力评估CTRCD的心肌改变;T2升高伴左心室质量减小在严重心功能障碍发生前即可出现;T2和定量LGE可能是CTRCD患者MACE的独立预后因素。
研究设计与样本
- 研究纳入2015年1月至2021年1月间接受心脏磁共振检查的145例癌症合并心力衰竭患者(男:女=76:69,平均年龄63.0岁),使用3T扫描仪(Siemens);比较有无CTRCD患者及轻中度与重度CTRCD患者间的双心室功能、原生T1、T2、细胞外容积分数(ECV)和左心室晚期钆增强(LGE);采用Cox比例风险回归分析CTRCD患者中磁共振参数与随访期间MACE发生的关联。
关键影像表现/征象
- CTRCD组原生T1为1336.9 ms,非CTRCD组为1303.4 ms(P=0.013)。
- CTRCD组ECV为32.5%,非CTRCD组为30.5%(P=0.010)。
- CTRCD组T2为44.7 ms,非CTRCD组为42.0 ms(P<0.001)。
- CTRCD组指数化左心室质量为65.0 g/m²,非CTRCD组为78.9 g/m²(P<0.001)。
- 原生T1、ECV和T2在轻中度与重度CTRCD患者间无显著差异。
诊断标准与关键数值
- 多变量Cox回归显示,CTRCD患者中T2与MACE独立相关(HR 1.14,95%CI 1.01-1.27;P=0.028)。
- 多变量Cox回归显示,CTRCD患者中定量LGE与MACE独立相关(HR 1.07,95%CI 1.01-1.13;P=0.021)。
临床应用与阅片要点
- 定量心脏磁共振参数可用于评估CTRCD患者的心肌改变。
- T2和定量LGE可能为CTRCD患者MACE的独立预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To quantitatively analyze the cardiac magnetic resonance imaging (CMR) characteristics of chemotherapy-related cardiac dysfunction (CTRCD) and explore their prognostic value for major adverse cardiovascular events (MACE).
MATERIALS AND METHODS: A total of 145 patients (male:female = 76:69, mean age = 63.0 years) with cancer and heart failure who underwent CMR between January 2015 and January 2021 were included. CMR was performed using a 3T scanner (Siemens). Biventricular functions, native T1 T2, extracellular volume fraction (ECV) values, and late gadolinium enhancement (LGE) of the left ventricle (LV) were compared between those with and without CTRCD. These were compared between patients with mild-to-moderate CTRCD and those with severe CTRCD. Cox proportional hazard regression analysis was used to evaluate the association between the CMR parameters and MACE occurrence during follow-up in the CTRCD patients.
RESULTS: Among 145 patients, 61 had CTRCD and 84 did not have CTRCD. Native T1, ECV, and T2 were significantly higher in the CTRCD group (1336.9 ms, 32.5%, and 44.7 ms, respectively) than those in the non-CTRCD group (1303.4 ms, 30.5%, and 42.0 ms, respectively; P = 0.013, 0.010, and < 0.001, respectively). They were not significantly different between patients with mild-to-moderate and severe CTRCD. Indexed LV mass was significantly smaller in the CTRCD group (65.0 g/m² vs. 78.9 g/m²; P < 0.001). According to the multivariable Cox regression analysis, T2 (hazard ratio [HR]: 1.14, 95% confidence interval [CI]: 1.01-1.27; P = 0.028) and quantified LGE (HR: 1.07, 95% CI: 1.01-1.13; P = 0.021) were independently associated with MACE in the CTRCD patients.
CONCLUSION: Quantitative parameters from CMR have the potential to evaluate myocardial changes in CTRCD. Increased T2 with reduced LV mass was demonstrated in CTRCD patients even before the development of severe cardiac dysfunction. T2 and quantified LGE may be independent prognostic factors for MACE in patients with CTRCD.
引用
- Kim J, Hong YJ, Han K, et al. Chemotherapy-Related Cardiac Dysfunction: Quantitative Cardiac Magnetic Resonance Image Parameters and Their Prognostic Implications. Korean J Radiol. 2023. PMID: 37634639. doi:10.3348/kjr.2023.0095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。